Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February
15 Sep 2023
Executive Change
Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras.
He takes the place of Longwood executive partner David Donabedian, who has taken the early CEO roles at a number of companies Longwood has backed, including Axial Therapeutics, ImmuneID and DEM BioPharma.
Vickers was previously head of Faze Medicines, a condensates biotech started by Third Rock that launched with $81 million in 2020 before shutting down at the end of last year.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.